A GLP-1 Blocker Just Passed Phase 3 Testing

A drug designed to block the GLP-1 receptor, rather than activate it the way Ozempic and Wegovy do, just passed a Phase 3 trial. It cut severe low blood sugar episodes by 55%, and participants gained no weight over 16 weeks. If you take a GLP-1, that second finding is the one that matters to you.

Nobody in the trial gained weight, in either group

Amylyx reported on August 18, 2026 that its drug avexitide met the primary endpoint of a Phase 3 trial called LUCIDITY, in 78 adults across 21 US sites (Amylyx). The release also reports no change in body weight in either the treatment group or the placebo group across the 16-week double-blind period.

Avexitide targets a specific exaggerated GLP-1 surge that happens after meals in a particular group of patients. It isn't a general appetite switch. Blunting one post-meal spike turns out to be a very different thing from shutting down the system your weekly injection works on. If you want the mechanism itself, our explainer on how these medications work covers it.

The limit: 16 weeks is 16 weeks, and is a very limited window of testing for a medication. There's a 32-week open-label extension still running to more thoroughly test the medication now.

This does not mean GLP-1 weight loss survives without the drug

If you read just the headline here, it sounds like you could stop taking your GLP-1 cold turkey and not see weight regain, and that isn’t what studies find. Keep in mind when reading this article, blocking the GLP-1 receptor in specific people had a positive effect on one health outcome, but it could have a very different one for you. In SURMOUNT-MAINTAIN, 378 people who had spent 60 weeks on tirzepatide were randomized to stay on it, drop to a lower dose, or move to placebo. By week 112 the placebo group had regained most of what they lost, and 67% of them needed rescue therapy against 8% of those who stayed at full dose (The Lancet). We covered that in our week-six guide.

Three things make the outcomes between blocking GLP-1 receptors for some people different from those using GLP-1s for health conditions.

Different starting point. LUCIDITY enrolled people who were weight-stable, and whose weight loss came from surgery years earlier rather than from a drug they were currently taking. SURMOUNT-MAINTAIN enrolled people who had just lost around a fifth of their body weight on a medication and were being taken off it.
Removing a drug is not the same as blocking a hormone. Stopping tirzepatide withdraws continuous appetite suppression well above anything your own hormones produce, and appetite returns. Avexitide blunts an abnormal post-meal spike back toward normal. Neither pushes your signaling below where it started.
The combination has not been tested. Nobody has given avexitide to someone currently on a GLP-1 who has lost significant weight on it. LUCIDITY doesn't tell us what that would do, and we won't guess.

So read the no-weight-change finding narrowly. Over 16 weeks, in weight-stable post-surgical patients, blunting a meal-time GLP-1 overshoot did not destabilize a weight that surgery was holding. This isn't evidence that anyone can stop a GLP-1 and keep the result.

The condition it treats comes from your own hormones, not from medication

Post-bariatric hypoglycemia, or PBH, is a complication of weight-loss surgery. After a gastric bypass or sleeve, food hits the small intestine faster, which triggers an oversized natural release of GLP-1, which tells the pancreas to release too much insulin. Blood sugar overshoots downward, usually one to three hours after eating.

Symptoms run from shakiness and sweating to the dangerous version, called neuroglycopenia, where the brain runs short of glucose and people get confused, lose consciousness, or have seizures.

This matters for our readers because the two groups overlap. GLP-1 medications are widely used after bariatric surgery for weight regain, so a meaningful number of people reading this had surgery first. If you're in that group and you get shaky or foggy an hour or two after eating, PBH is a real thing to raise with your care team. A 2025 review notes it's frequently misdiagnosed for years because the symptoms are vague (J Am Board Fam Med).

One point of precision. Your medication is not causing PBH. The little published work that exists points the other way, suggesting semaglutide may improve reactive low blood sugar after bariatric surgery by slowing gastric emptying for those who fall into both treatment categories. That literature is small and mostly retrospective or single-case, so treat it as a working hypothesis rather than settled. Either way, nobody should read this as a reason to stop a GLP-1.

The trial cut moderate and severe crashes by 55%

The primary endpoint, which Amylyx says was agreed with the FDA, was the reduction in the composite rate of Level 2 and Level 3 low blood sugar events through week 16. Avexitide cut that rate by 55% against placebo, with a p-value of 0.000003. The company says all secondary endpoints were met and names three of them, without releasing individual figures.

Using the American Diabetes Association classification, Level 2 means glucose below 54 mg/dL and Level 3 means an event severe enough to need another person's help, irrespective of the glucose reading (ADA Standards of Care). There isn't an FDA-approved treatment for PBH, so people manage it with dietary change plus off-label options including acarbose, diazoxide and octreotide. On surgery, that same review reports gastric bypass reversal has variable results and should be assessed beforehand, and that partial pancreatectomy isn't recommended unless there's a coexisting insulinoma (J Am Board Fam Med).

Treat these figures as company topline from a press release and an investor call. They haven't been published in a journal or presented at a medical meeting.

This is not an antidote for GLP-1 side effects

There isn't any research on using a GLP-1 blocker to reverse the effects of GLP-1 medication, whether for severe nausea, a dosing error, or an overdose. No trials, no preclinical work, no expert commentary, and nothing in Amylyx's own materials. Avexitide's target is your body's own hormone overshoot, not a drug you injected.

If you've taken too much of a GLP-1, this drug is not the answer and isn't available publicly anyway. Call your prescriber or poison control.

Avexitide is not approved and has not been filed

Status as of August 25, 2026:

Not submitted. Amylyx says it plans to file a New Drug Application by the end of 2026.
No PDUFA date exists, because that target review date is only set after the FDA accepts a submitted application.
It holds Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designation, but not Fast Track. The Orphan Drug designation covers hyperinsulinemic hypoglycemia, which includes PBH and congenital hyperinsulinism rather than PBH alone. Fast Track belongs to a different Amylyx candidate in ALS (Amylyx pipeline).
Launch "in 2027, if approved" is a company projection contingent on filing, acceptance and review (BioSpace).

One more limit. LUCIDITY enrolled people with PBH after gastric bypass only, not after sleeve gastrectomy, so any eventual label may be narrower than "after bariatric surgery."

Final Takeaway

For most readers the useful takeaway isn't the drug, it's the biology. GLP-1 is a system with a dose-response curve rather than an on-off switch, so blunting one exaggerated post-meal spike in weight-stable patients behaves nothing like withdrawing a medication from someone who just lost 20% of their body weight on it.

If you had bariatric surgery and you crash after meals, bring PBH up by name with your care team, because it gets missed for years. And if you're just trying to work out whether your own medication is doing its job, our week-six guide is the more useful page.

If you enjoy posts like these, you can subscribe to receive newsletter updates.

Blocking GLP-1 for 16 Weeks Caused No Weight Regain for Those with Post-Bariatric Hypoglycemia

Nobody in the trial gained weight, in either group

This does not mean GLP-1 weight loss survives without the drug

The condition it treats comes from your own hormones, not from medication

The trial cut moderate and severe crashes by 55%

This is not an antidote for GLP-1 side effects

Avexitide is not approved and has not been filed

Final Takeaway

Sources

Keep Reading

The New Federal Protein Target and What It Means on a GLP-1

The FDA Wants to Limit Where Compounded GLP-1s Come From

The FTC Sued Hims & Hers: What GLP-1 Subscribers Should Check

Categories

Curated by